This website uses cookies

We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. We will only use cookies based on your decision.

NaF PET/CT in prostate cancer

By Kristin Schmiedehausen, MD|01/01/2015

Prostate cancer is the second most common cancer in men worldwide.1 Explore the role of PET/CT and the bone-seeking radiopharmaceutical Sodium Fluoride F18 Injection (18F NaF), which together can be an accurate technique for imaging skeletal metastases high-risk patients. Download the white paper below to discover the incremental value of this imaging technique and how this technique might be able to provide additional, valuable information for response management, prognostication, and therapy planning for radionuclide therapy.

1
Subscription Button Icon
Be the first to know about our events, training, and news